PRZOOM - /newswire/ -
North Miami, FL, United States, 2011/10/31 - Peg Esper, MSN, MSA, RN, APRN-BC, AOCN®, of the University of Michigan Comprehensive Cancer Center leads a CE-certified satellite symposium to foster clinical competence of the application of emerging data regarding immunotherapeutic agents.
This activity will broadcast live. Additional details pertaining to joining this activity via live Webcast will be provided upon registration. Oncology healthcare professionals from all over the world are invited to participate.
Friday, November 4, 2011
6:00 AM—7:30 AM Mountain Time
Salt Lake City Marriott Downtown
Physician assistants, nurse practitioners, clinical nurse specialists, and other healthcare professionals who are involved in the use of immunotherapeutic agents to treat cancer are invited to join Peg Esper, MSN, MSA, RN, APRN-BC, AOCN®, Susan F. Slovin, MD, PhD, FACP, of Memorial Sloan-Kettering Cancer Center, and Krista M. Rubin, MS, RN, FNP-BC, of Massachusetts General Hospital as they present the clinical advancements in immunologic science that have led to the evolution of immunotherapeutic agents as cancer treatment, as evident by the FDA approval of two new cancer immunotherapies.
In contrast to conventional therapies, immunotherapy holds the promise of a durable antitumor immune response maintained over the course of a patient’s lifespan.
This satellite symposium will include key considerations related to the pharmacology and administration of immunotherapies, management of immune-related adverse events, and typical response patterns among this class of agents.
Two interactive case studies highlighting current research on immunotherapeutic agents used for prostate cancer and melanoma treatment will demonstrate evidence-based strategies for optimal assessment and management of patients receiving these therapies.
By the end of this broadcast, participants should be better able to:
• Identify the types and mechanisms of immunotherapy in cancer
• Review the administration guidelines for approved immunotherapeutic agents
• Describe how novel immunotherapies have been incorporated into national practice guidelines
• Assess emerging data from recent and ongoing clinical trials of cancer immunotherapies
• Evaluate the unique patterns of response and monitoring parameters associated with cancer immunotherapies
• Apply best supportive care practices for the assessment and management of adverse events associated with cancer immunotherapies
• Integrate national guidelines, response pattern monitoring, and strategies to mitigate immune-related adverse events into individualized treatment planning
To register for this satellite broadcast, please visit IMERonline.com/webcastimmunotherapies.
You may also register to attend this satellite symposium on site if you are planning to attend the ONS 12th Annual IOL in Salt Lake City, Utah by visiting IMERonline.com/.
This conference is sponsored by the Institute for Medical Education & Research. The program is supported by an educational grant from Bristol-Myers Squibb.